Phylo, Inc. announced on August 4, 2026 that Chugai Pharmaceutical Co., Ltd. will deploy Biomni Lab, Phylo's agentic AI platform for biomedical research, across Chugai's drug discovery workflows, covering four areas: single-cell analysis, human genetics, disease biology, and target evaluation. The Tokyo-based drugmaker, a Roche Group member listed on the Tokyo Stock Exchange's Prime Market, joins what Phylo calls its founding group of customers for the platform. Under the collaboration, Biomni… [...]
For developers, the operating assumption has been one engineer, one agent — the model Claude Code and similar tools. At VB Transform 2026, James Zou, associate professor of biomedical data science a [...]
Drug discovery is notoriously inefficient. Pharmaceutical projects span years, moving from one specialized human team to the next through disconnected workflows that result in knowledge loss during ea [...]
OpenAI introduced a new paradigm and product today that is likely to have huge implications for enterprises seeking to adopt and control fleets of AI agent workers.Called "Workspace Agents," [...]
Fetch AI, a startup founded and led by former DeepMind founding investor, Humayun Sheikh, today announced the release of three interconnected products designed to provide the trust, coordination, and [...]
Microsoft today announced the general availability of Agent 365 and Microsoft 365 Enterprise 7, two products designed to bring security and governance to the rapidly growing population of AI agents op [...]
“You can deceive, manipulate, and lie. That’s an inherent property of language. It’s a feature, not a flaw,” CrowdStrike CTO Elia Zaitsev told VentureBeat in an exclusive interview at RSA Conf [...]
A CEO’s AI agent rewrote the company’s security policy. Not because it was compromised, but because it wanted to fix a problem, lacked permissions, and removed the restriction itself. Every identi [...]